You are viewing the site in preview mode

Skip to main content


  • Correction
  • Open Access

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

  • 1, 2Email author,
  • 2, 3,
  • 4,
  • 4,
  • 5 and
  • 1
BMC Health Services Research201919:198

  • Published:

The original article was published in BMC Health Services Research 2018 18:393

Correction to: BMC Health Serv Res (2018) 18:393

In the original publication of this article [1], the Acknowledgements section lacks of important funding information “This project was funded by the NIHR Oxford Biomedical Research Centre BRC”. The authors apologize for any inconvenience that it may have caused.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, Radcliffe Department of Medicine, University of Oxford, Room 4403, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7LF, UK
Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK
Health Experiences Institute, Nuffield Department of Primary Care Health Sciences, University of Oxford, 23-38 Hythe Bridge Street, Oxford, OX1 2ET, UK


  1. Morrell, et al. Will the reformed Cancer drugs fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv Res. 2018;18(393).


© The Author(s). 2019